3 Things to Watch in Merck's Upcoming Earnings

Earnings season has been a mixed bag for big pharma so far this month, but the industry has a chance to score a big victory for investors when Merck (NYSE: MRK  ) reports its quarterly results next Wednesday. Merck has struggled with the patent cliff, like many of the top names in big pharma recently, and top drugs such as the diabetes-fighting duo Januvia and Janumet have struggled to gain significant sales growth.

Still, Merck has plenty going for its stock as one of the biggest names in health care. The firm's developmental cancer therapy, MK-3475, in particular has garnered high praise from analysts. Merck recently filed MK-3475 for regulatory approval in the U.S. as a melanoma treatment, and analysts project that the drug could one day garner up to $3 billion in annual sales if Merck can score approvals for more uses of the therapy.

MK-3475's development is one thing to watch in Merck's upcoming performance report, but what else do you need to keep an eye on? Find out what to watch from this top big pharma stock in the video below, as Motley Fool contributor Dan Carroll goes through the three most important things investors need to look out for in Merck's earnings -- and how they could make or break this stock heading into 2014.

Is Merck the right dividend for you?
Merck and other big pharma stocks have emerged as some of the top dividend-paying stocks on the market, but any great investor knows the power of diversifying your portfolio. If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2818151, ~/Articles/ArticleHandler.aspx, 9/5/2015 8:40:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:01 PM
MRK $51.59 Down -1.06 -2.01%
Merck & Co., Inc. CAPS Rating: ****
JNJ $91.31 Down -1.33 -1.44%
Johnson & Johnson CAPS Rating: ****
NVS $94.55 Down -0.81 -0.85%
Novartis CAPS Rating: ****